Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Renalytix Shares Fall as Commercial Scale-Up Lags Clinical Validation

Renalytix plc (LSE:RENX) develops and commercialises prognostic testing for kidney disease. Its lead product assesses the risk of rapid decline in kidney function among adults with type 2 diabetes and early-stage chronic kidney disease, combining blood-based markers with clinical record data. The test has …

Ankur Sharma | 22 September 2026

Fusion Antibodies Shares Weaken as Order Flow and Funding Requirements Stay in Focus

Fusion Antibodies plc (LSE:FAB) provides contract research services to drug developers, specialising in antibody engineering, humanisation, characterisation and related preclinical work. Its clients are typically biotechnology companies advancing therapeutic candidates towards clinical development. The case depends heavily on the funding environment for those clients, …

Ankur Sharma | 22 September 2026

IXICO Shares Slip as Investors Weigh Order Book Strength Against Cash Discipline

IXICO plc (LSE:IXI) supplies neuroscience imaging and biomarker analytics to companies and institutions developing treatments for neurological disorders. Its platform measures imaging markers associated with conditions such as Alzheimer’s, Huntington’s and Parkinson’s diseases. TheInvestmentcase combines a specialised serviceBusinesswith an ambition to license technology more …

Ankur Sharma | 22 September 2026

Worldwide Healthcare Trust Rises as Biotech M&A Basket Fuels a Return to Form

Worldwide Healthcare Trust plc shares rose 0.13% today to around 380.00p, extending a period of renewed strength for the specialist global healthcareInvestmenttrust following a strong return to form in its most recent financial year.

Divya Sood | 22 September 2026

SkinBioTherapeutics Shares Slide as Cash Pressure and Governance Concerns Cloud Recovery

SkinBioTherapeutics Plc (LSE:SBTX), quoted on the London Stock Exchange’s AIM market, develops and commercialises skin-health products and technology. Its activities combine topical skincare, oral supplements, licensing and contract manufacturing. Investor sentiment remains vulnerable because commercial growth has yet to establish sustainable profitability. For smaller …

Ankur Sharma | 22 September 2026

ioventix Shares Under Pressure as Growth Concerns Cloud the Dividend and Recovery Outlook

The supplied market snapshot indicates a -5.88% decline. No verified announcement establishing the cause of that session’s movement was identified, so attributing the fall to a fresh operational setback or institutional selling would be speculative.

Ankur Sharma | 22 September 2026

ImmuPharma Shares Fall 8.30% as Funding Sensitivity and Commercial Uncertainty Weigh on Sentiment

The supplied market snapshot shows ImmuPharma down by -8.30%. A definitive company-specific cause for that session’s movement could not be independently established. Funding sensitivity, uncertainPartnershiptiming and speculative selling are plausible interpretations rather than confirmed explanations.

Ankur Sharma | 22 September 2026

Abingdon Health Shares Fall as Contract Timing and Profitability Risks Weigh on Growth Prospects

Abingdon Health Plc (LSE:ABDX) develops and manufactures rapid diagnostic tests and provides associated technical and regulatory services. Its shares trade on the London Stock Exchange’s AIM market. TheBusinessoffers exposure to outsourced diagnostic development, but customer funding, technical milestones and commercialisation schedules can make revenue …

Ankur Sharma | 22 September 2026

Why Is Diaceutics PLC (LSE:DXRX) Stock Rising 5.88% Today as 75% ARR Growth and H1 Results Put Precision Medicine in Focus?

Diaceutics PLC is attracting attention on 22 September 2026 because the company is scheduled to report its unaudited results for the six months ended 30 June 2026.

Ankur Sharma | 22 September 2026

EDX Medical Stock Gains 8.33%: Could New Diagnostic Services and NHS Projects Drive the Next Growth Phase?

EDX Medical Group LSE:EDX is attracting attention after gaining8.33% on 22 September 2026, making it one of the stronger healthcare movers in the UK market list being monitored.

Ankur Sharma | 22 September 2026
Support

Hi! How can we help you today?

Loading…